COVID-19 Impact Analysis on Europe Induced Pluripotent Stem Cells Market
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the Europe induced pluripotent stem cells market. In addition, complete analysis of changes on the Europe induced pluripotent stem cells market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. After its outburst in China in December 2019, COVID-19 began to spread rapidly across the globe, in just a few months reaching all countries; in Europe, it reached a large scale spread in the spring of 2020. Although Western European countries benefit from high-performance health systems, the COVID-19 crisis has severely brought Italy, Spain, France and the UK to the forefront of the crisis: Spain (566326), United Kingdom (3651789), France (353986), Italy (286297) and Germany (259428). Eastern European countries, with weaker health systems, coped better with this crisis, in the first phase. Against this background, the legitimate question is how this overwhelming difference in the efficiency of health systems occurred in the first wave of the crisis. However, in the relaxation period, and in the second wave, the roles change: the Western states with better sanitary systems manage to respond more adequately to the crisis; instead, the Eastern states are undergoing dramatic negative changes. Therefore, if at the beginning of the pandemic there was a stronger destabilization in terms of health of Western European economies compared to those in the East. Later, starting with the summer of 2020, it turned out that states that demonstrated prompt action capabilities, adapted context, were those who managed to outline the premises of a considerable decrease in the number of infections. In addition, the relationship between resources and needs has been streamlined, in order to minimize the risk of blockages in intensive care units, in terms of the number of existing beds or specialized medical staff.
Market Overview- Europe Induced Pluripotent Stem Cells Market
Growing investment in basic level research, especially by research organizations and academic institutes in the last few years has led to an increased understanding of the fundamental pathways through which induced pluripotent stem cells implicated in disease development are either up or down-regulated. This leads to more questions about how biology works, the cause of the diseases and potential diagnoses and treatments. Induced pluripotent stem cells display a particular gene expression signature that is similar to that of embryonic stem cells and exhibit both pluripotency and the capacity of self-renewal. In the recent past, the complexity of products requested by researchers has grown and this suggests improvement in understanding of the basic pathways and discovery of some new pathways. It is important for manufacturers of research products to keep up with the latest developments to cater to the ever-changing requirements of the life sciences industry.
Stem cell research is attracting wide attention as a promising and fast-growing field in Europe, as it is worldwide. Many countries in the region have defined Regenerative Medicine as a research priority and a focus of investment. This field generates not only opportunities but also regulatory, technical and operative challenges. Europe is a fast-growing region conscious of the relevance of stem cell research for the development of Regenerative Medicine, which we think will play a major role in healthcare.
Factors like high cost associated with the reprograming of cells, ethical issues and lengthy processes are impeding the induced pluripotent stem cells market growth. Low efficiency, potential tumour risk and incomplete programming are added factors limiting induced pluripotent stem cells market growth.
Stem cell therapy comprises a modern technology whose aim is to substitute damaged cells with healthy new ones. Cells are rendered dysfunctional due to any number of factors such as aging, disease, genetic modification, injury. Nowadays, Stem cell therapies are providing substantial benefit to patients suffering a wide range of diseases such as cancer, non-cancer, neuronal disease, diabetes and injuries such as brain trauma and spinal cord injuries. It is well established and rapidly growing in developed country however in developing country, there are several challenges which is shielding the booming of this therapy. Owing to that, it is expected to eventually remove these challenges to create the fresh environment of modern stem cell therapeutic medicine.
Cumulative Growth Analysis
The report provides in-depth analysis of Europe induced pluripotent stem cells market, market size, and compound annual growth rate (CAGR) for the forecast period of 2022-2028, considering 2021 as the base year. With increasing demand for various induced pluripotent stem cells in various applications has led the increasing demand for market and is expected to witness the growth at a specific CAGR from 2022-2028.
Market Segmental Overview
The Europe induced pluripotent stem cells market comprises of different market segment like derived cell type, product, processes, application, end user and Country.
Europe Induced Pluripotent Stem Cells Market by Derived Cell Type
The various derived cell types comprised in the reports are hepatocytes, fibroblasts, keratinocytes and amniotic cells. The keratinocytes segment is also contributing to the growth of Europe induced pluripotent stem cells market. Keratinocyte-derived iPS (KiPS) cells appear indistinguishable from human embryonic stem cells in colony morphology, growth properties, expression of pluripotency-associated transcription factors and surface markers, global gene expression profiles and differentiation potential in vitro and in vivo.
Europe Induced Pluripotent Stem Cells Market by Product
The certain products comprised in the global induced pluripotent stem cells market are instruments/devices, automated platforms, consumables and kits and services. The instruments/devices segment is likely to dominate the market during the forecast period. The biopharma industry is continuing to adapt more cell-based assays for primary and secondary screening because of higher biological relevance and increased value of information. As part of this evolution, there is a desire to move from immortalized, stable cell lines to primary cells and stem cells. Stem cells offer the advantages of providing better clinical relevance of information compared to cell lines, being available in larger quantities, and having higher assay reproducibility than primary cells. Therefore, there is a great interest in automated stem cell assays to use as screening tools in early drug development, and to evaluate potential toxic effects of new compounds.
Europe Induced Pluripotent Stem Cells Market by Process
The various processes such as manual and automated are comprised in the report are manual and automated. The manual segment is also contributing to the growth of the growth of the Europe induced pluripotent stem cells market. The factors such as ability to make any cell or tissue the body might need coupled with government and private sectors are sectors are increasing funding and rising industry that focuses on different research work.
Europe Induced Pluripotent Stem Cells Market by Application
The various applications of induced pluripotent stem cells comprised in the report are drug development and discovery, toxicity screening and regenerative medicines. The regenerative medicines is also contributing to the growth of the Europe induced pluripotent stem cells market. The drug development and discovery segment is likely to dominate the market during the forecast period. Stem cells are fast becoming an invaluable tool in the drug discovery process. Stem cells offer the remarkable capacity to generate an unlimited source of disease relevant cell types from which to identify novel molecular targets, perform large-scale phenotypic screens and also identify off-target toxicities.
Europe Induced Pluripotent Stem Cells Market by End Users
The various end users comprised in the report are hospitals, research laboratories and academic research. The academic research segment is also contributing to the growth of Europe induced pluripotent stem cells market. The growing focus towards the academic research coupled with growing investment in basic level research especially by research organizations and academic institutes in the past few years. which has led to increase in knowledge of the basic pathways through which induced pluripotent stem cells implicated in the disease development are also up or down regulated.
Europe Induced Pluripotent Stem Cells Market by Country
The countries such as U.K., Germany, France, Italy and Spain are comprised in the Europe induced pluripotent stem cells market. The U.K. is anticipated to dominate the market in 2021. Followed by Germany and the France. The large share of the U.K. market is attributed to the rising incidence of cancer and growing research activity in cancer and stem cells. The rising investment in pharmaceutical R&D is also boosting growth of cell and gene therapy manufacturing services market.
Competitive Landscape Analysis
The competitive landscape analysis of induced pluripotent stem cells market is certainly based range of market players operating in the healthcare market with increasing demand for production of induced pluripotent stem cells market. Besides, number of market players offered wide range of products for different application in various geographic locations. The market has major competitive analysis based on new product launches as well as other developments.
The key players studied in market are Fujifilm Holding Corporation, Astellas Pharma Inc., Fate Therapeutics, Inc., Bristol-Myers Squibb Company, ViaCyte, Inc., Celgene Corporation, Aastrom Biosciences, Inc., Acelity Holdings, Inc., StemCells, Inc., Japan Tissue Engineering Co. Ltd. and Organogenesis Inc. among others.
June 2021: Thermo Fisher Scientific Inc. announced that it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company footprints in global market and leading to upsurge company growth in the upcoming years.
June 2020: The LumaCyte collaborated with Catalent who are the global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. This collaboration aided in expanding the company stem cell technology product Radiance and its application.